chevron_leftBack
As of 14 June 2026, Synlogic, Inc. has a market cap of $6.55M USD, ranking #43362 globally and #5549 in the United States.
It ranks #3838 in the Healthcare sector, and #755 in the Biotechnology industry.
Key Stats
Market Cap
$6.55MUSD
Enterprise Value
-$9.04MUSD
EBITDA (TTM)
-$3.6MUSD
Net Income (TTM)
-$3.23MUSD
PB Ratio
0.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mary Dooley
open_in_new
Employees
1
Website
synlogictx.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -50% | -50% | -53% | -69% | -68% | -62% |
News
Loading...
SYBX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SYBX
Synlogic Inc
ISIN: US87166L2097
Shares Out.:
Shares Outstanding:
11.699M1
Shares Float:
7.095M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.5600 USD | |
|
0A8U
Synlogic Inc
ISIN: US87166L2097
Shares Out.:
Shares Outstanding:
11.697M1
Shares Float:
9.603M2
|
0.6400 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Synlogic, Inc.
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
3M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
421K%
|
-
|
|
NYSE: IQV
|
$26.3B
401K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
382K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
277K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
730K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
684K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
647K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
646K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
429K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
392K%
|
-
|
chevron_leftBack